The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

1 Citaat (Scopus)


The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

Originele taal-2Engels
TijdschriftJournal of Translational Medicine
Nummer van het tijdschrift1
StatusGepubliceerd - dec. 2021


Duik in de onderzoeksthema's van 'The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020'. Samen vormen ze een unieke vingerafdruk.

Citeer dit